Skip to main content
OpenTrials
Completed

NCT Number: NCT04059289

Intermediate Vision in a Driving Simulator Environment: Comparison of the J&J EYHANCE With a Conventional Monofoc. IOL

To compare (low contrast) visual acuity (VA) and contrast sensitivity (CS) - both at intermediate distances under nighttime driving conditions in a driving simulator between patients with bilateral EYHANCE IOLs OR bilateral conventional monofocal IOLs. Visual function testing in the driving simulator will be assessed without AND with (static) glare.

Additionally: Assessment of individual response times, scanpath characteristics, evaluation of test retest reliability and self-evaluation of (intermediate) vision and visual impairment related to glare.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Applied Sciences, Study Course Ophthalmic Optics

Aalen, Baden-Wurttemberg, 73430, Germany

About this study

To compare (low contrast) visual acuity (VA) and contrast sensitivity (CS) - both at intermediate distances under nighttime driving conditions in a driving simulator between patients with bilateral EYHANCE IOLs OR bilateral conventional monofocal IOLs. Visual function testing in the driving simulator will be assessed without AND with (static) glare.

Additionally: Assessment of individual response times, scanpath characteristics, evaluation of test retest reliability and self-evaluation of (intermediate) vision and visual impairment related to glare.

Simulator

Patients are instructed to drive with a constant speed of 40 km/h on a virtual parcours (straight lane). For testing of either (low contrast) visual acuity or contrast sensitivity, 8-position LANDOLT C's are presented at three locations (within the simulator car, AUDI A4, Ingolstadt/FRG):

(i) At the center of the instrument panel (distance 0.xx m) (ii) At the center of the navigation monitor (y.yy m) (iii) At the center of the rear monitor (z.zz m) A high resolution acoustic attention guidance for immediate gaze direction of the patients towards the three above-mentioned visual stimulus locations (i-iii) is mandatory.

Patients responses are recorded and response times can be extracted from the recordings.

Clinical ophthalmological-optical examinations

  • Medical/ophthalmological history
  • (Uncorrected and Best-corrected) visual acuity (RE,LE,BE) with remote and intermediate (66cm) 8 position LANDOLT C's.
  • LANG I stereotest (near distance)
  • Ocular alignment & ocular motility
  • Efferent & afferent pupillomotor status
  • Mesopic contrast sensitivity without/with glare (Optovist, VISTEC Inc./Olching/FRG)
  • Intraocular straylight perception (Q-Quant, OCULUS Inc, Wetzlar/FRG)
  • Slit lamp (anterior segment)
  • Ophthalmoscope (central fundus and fixation)
  • Primary objectives: log visual acuity (logVA) at preset low contrast level of 1:2.7 (logCS = 0.2) AND log contrast sensitivity (logCS) at a preset visual acuity level of 0.1 = 2/20)
  • Secondary objectives: test retest reliability (as operationalized by LOA = limits of agreement) AND response time (i.e. time interval between onset of stimulus presentation and final response) AND scanpath characteristics (fixation duration, fixation stability, annotation to regions of interest; saccade amplitude) self-evaluation (questionnaire, using visual analogue scales = VAS)

SHAPIRO WILK test (statistical testing for proving/disproving normal distribution) Descriptive statistics (either MEAN, standard deviation, in case of normally distributed data - else, MEDIAN, inter-quartile range (IQR).

Assessment of test/retest reliability: BLAND ALTMAN plots, limits of agreement (LOA) Between-group comparison: t-test (unpaired samples), in case of normally distributed data - else, WILCOXON signed-rank test

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent
  • S.p. (at least two months post surgery) bilateral uneventful IOL surgery (bilateral implantation of either EYHANCE IOL OR monofocal IOL)
  • Ophthalmological history normal, except cataract and uneventful IOL surgery
  • Distant visual high-contrast acuity > 20/25 in either eye
  • Normal stereopsis (all figures of the LANG I random dot stereo test correctly recognized)

Exclusion criteria

  • Age below 18 years
  • Chronic eye disease (except cataract)
  • History of ocular surgery (except complication-free IOL surgery)
  • Visual pathway lesions
  • Strabismus

Treatment and study plan

Posterior chamber intraocular lens (IOL)

Other

This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study

Other names: Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA), Clareon IOL (Alcon Pharma. Freiburg/FRG)

Primary outcomes

  1. logVA

    Time frame: at least two months after uneventful intraocular lens implantation

    logarithm of visual acuity at preset low contrast level of 1:2.7 (logCS = 0.2)

  2. logCS

    Time frame: at least two months after uneventful intraocular lens implantation

    logarithm of contrast sensitivity at a preset visual acuity level of 0.1 (= 2/20)

Secondary outcomes

  1. Reproducibilities of logVA

    Time frame: at least two months after uneventful intraocular lens implantation

    as operationalized by LOA (limits of agreement)

  2. Resonse times of logCS

    Time frame: at least two months after uneventful intraocular lens implantation

    time interval between onset of stimulus presentation amd final response

  3. Scanpath characteristics (I)

    Time frame: at least two months after uneventful intraocular lens implantation

    fixation duration

  4. Scanpath characteristics (II)

    Time frame: at least two months after uneventful intraocular lens implantation

    fixation stability

  5. Scanpath characteristics (III)

    Time frame: at least two months after uneventful intraocular lens implantation

    annotation to regions of interest (ROIs)

  6. Scanpath characteristics (IV)

    Time frame: at least two months after uneventful intraocular lens implantation

    saccade amplitude

  7. Self-evaluation (questionnaire) (i) distant vision with best distant correction

    Time frame: at least two months after uneventful intraocular lens implantation

    Distant vision (self-eval., vis. analogue scales: 0 = unsatisfactory ... 10 = optimal)

  8. Self-evaluation (questionnaire) (i) intermediate vision with best distant correction

    Time frame: at least two months after uneventful intraocular lens implantation

    Intermed. vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)

  9. Self-evaluation (questionnaire) (i) mesopic vision with best distant correction

    Time frame: at least two months after uneventful intraocular lens implantation

    Mesopic vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)

  10. Self-evaluation (questionnaire) (i) glare sensitivity with best distant correction

    Time frame: at least two months after uneventful intraocular lens implantation

    Glare sensitivity (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)

  11. Self-evaluation (questionnaire) (i) General post-op vision with best distant corr.

    Time frame: at least two months after uneventful intraocular lens implantation

    Post-op vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)

Sponsors and collaborators

Lead sponsor

Aalen University

Other

Collaborators

  • University Hospital Tuebingen

Registry information

Official study title

Intermediate Vision in a Driving Simulator Environment: Comparison of the New J&J EYHANCE IOL With a Conventional Monofocal IOL

Acronym: JJ-EYHANCE

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Aug 16, 2019
Registry last updated
Mar 31, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.